Galapagos NV (Galapagos NV) Dividend Payout Ratio

: 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Galapagos NV's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Galapagos NV's Dividend Payout Ratio or its related term are showing as below:

GLPG's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.4
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-19), the Dividend Yield % of Galapagos NV is 0.00%.

Galapagos NV's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Galapagos NV Dividend Payout Ratio Historical Data

The historical data trend for Galapagos NV's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Galapagos NV's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV Dividend Payout Ratio Distribution

For the Biotechnology industry and Healthcare sector, Galapagos NV's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Dividend Payout Ratio falls into.

Galapagos NV Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Galapagos NV's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	Earnings per Share (Diluted) (A: Dec. 2023 )
	=	0	/	3.501
	=	0.00

Galapagos NV's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	Earnings per Share (Diluted) (Q: Dec. 2023 )
	=	0	/	2.606
	=	0.00

Galapagos NV (NAS:GLPG) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Galapagos NV Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.